Literature DB >> 16914214

Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187.

Bronislava R Gedulin1, Carolyn M Jodka, Kathrin Herrmann, Andrew A Young.   

Abstract

Amylin is a 37-amino acid polypeptide co-secreted with insulin from the pancreatic beta-cells. It complements insulin's stimulation of the rate of glucose disappearance (Rd) by slowing the rate of glucose appearance (Ra) through several mechanisms, including an inhibition of mealtime glucagon secretion and a slowing of gastric emptying. To determine if endogenous amylin tonically inhibits these processes, we studied the effects of the amylin receptor blocker AC187 upon glucagon secretion during euglycemic, hyperinsulinemic clamps in Sprague-Dawley (HSD) rats, upon gastric emptying in HSD rats, and upon gastric emptying and plasma glucose profile in hyperamylinemic, and genetically obese, Lister Albany/NIH rats during a glucose challenge. Amylin blockade increased glucagon concentration, accelerated gastric emptying of liquids, and resulted in an exaggerated post-challenge glycemia. These data collectively indicate a physiologic role for amylin in glucose homeostasis via mechanisms that include regulation of glucagon secretion and gastric emptying.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914214     DOI: 10.1016/j.regpep.2006.06.004

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  21 in total

Review 1.  Bowels control brain: gut hormones and obesity.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes.

Authors:  R J Bailey; C S Walker; A H Ferner; K M Loomes; G Prijic; A Halim; L Whiting; A R J Phillips; D L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys.

Authors:  Nicholas T Bello; Matthew H Kemm; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-05-14       Impact factor: 3.619

Review 5.  Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Authors:  Magnus F Grøndahl; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

Review 6.  Control of energy homeostasis by amylin.

Authors:  Thomas A Lutz
Journal:  Cell Mol Life Sci       Date:  2011-12-23       Impact factor: 9.261

Review 7.  Adjunct therapy for type 1 diabetes mellitus.

Authors:  Harold E Lebovitz
Journal:  Nat Rev Endocrinol       Date:  2010-04-20       Impact factor: 43.330

8.  Human islet amyloid polypeptide at the air-aqueous interface: a Langmuir monolayer approach.

Authors:  Shanghao Li; Miodrag Micic; Jhony Orbulescu; Jeffrey D Whyte; Roger M Leblanc
Journal:  J R Soc Interface       Date:  2012-07-11       Impact factor: 4.118

9.  Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR.

Authors:  Sorin Luca; Wai-Ming Yau; Richard Leapman; Robert Tycko
Journal:  Biochemistry       Date:  2007-11-03       Impact factor: 3.162

10.  Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.

Authors:  Matthew Riddle; Richard Pencek; Supoat Charenkavanich; Karen Lutz; Ken Wilhelm; Lisa Porter
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.